{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:18:58Z","timestamp":1792883938843,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227209\/Z\/23\/Z"],"award-info":[{"award-number":["227209\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008522"],"award-info":[{"award-number":["INV-008522"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-057216"],"award-info":[{"award-number":["INV-057216"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128690","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:35:58Z","timestamp":1778607358000},"page":"128690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design and feasibility considerations for a phase 3 efficacy trial of the M72\/AS01E-4 tuberculosis vaccine"],"prefix":"10.1016","volume":"85","author":[{"given":"Alemnew F.","family":"Dagnew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlina","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Fairlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monde","family":"Muyoyeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C.","family":"Mwandumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Videlis","family":"Nduba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128690_bb0005","series-title":"Global tuberculosis report 2025","author":"World Health O","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128690_bb0010","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S1473-3099(22)00153-0","article-title":"Are we underestimating the annual risk of infection with mycobacterium tuberculosis in high-burden settings?","volume":"22","author":"Dowdy","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0015","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG revaccination for the prevention of mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5588\/ijtldopen.25.0684","article-title":"Interferon-gamma release assay positivity in populations at high risk of tuberculosis infection","volume":"3","author":"Dagnew","year":"2026","journal-title":"IJTLD Open"},{"key":"10.1016\/j.vaccine.2026.128690_bb0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/cid\/ciae357","article-title":"Conversion or reversion of interferon gamma release assays for mycobacterium tuberculosis infection: a systematic review and Meta-analysis","volume":"80","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004340","article-title":"Prediction models for Mtb infection among adolescent and adult household contacts in high tuberculosis incidence settings","volume":"5","author":"Marambire","year":"2025","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128690_bb0035","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128690_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiology & Infection"},{"key":"10.1016\/j.vaccine.2026.128690_bb0045","series-title":"TB 101 \u2013 Risk of developing TB disease (1\/2)","author":"Control CfD, Prevention","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128690_bb0050","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1164\/rccm.201206-1134OC","article-title":"Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents","volume":"186","author":"Machingaidze","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0055","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/joim.13197","article-title":"New tuberculosis vaccines: advances in clinical development and modelling","volume":"288","author":"Weerasuriya","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0060","series-title":"Evidence considerations for vaccine policy development for tuberculosis vaccines intended for adults and adolescents","author":"World Health O","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128690_bb0065","series-title":"WHO preferred product characteristics for new tuberculosis vaccines","author":"Organization WH","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128690_bb0070","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"Knight","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128690_bb0075","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1017\/S0950268818000821","article-title":"Incidence and prevalence of bacteriologically confirmed pulmonary tuberculosis among adolescents and young adults: a systematic review","volume":"146","author":"Snow","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128690_bb0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/trstmh\/trz049","article-title":"Age-specific prevalence of TB infection among household contacts of pulmonary TB: is it time for TB preventive therapy?","volume":"113","author":"Dolla","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.128690_bb0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/tropicalmed6030148","article-title":"Tuberculosis in adolescents and young adults: emerging data on TB transmission and prevention among vulnerable young people","volume":"6","author":"Laycock","year":"2021","journal-title":"Tropical Medicine and Infectious Disease"},{"key":"10.1016\/j.vaccine.2026.128690_bb0090","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0095","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0100","series-title":"Design of vaccine efficacy trials to be used during public health emergencies: Points of consideration and key principles","author":"World Health O","year":"2020"},{"key":"10.1016\/j.vaccine.2026.128690_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae104","article-title":"Past, present, and future of phase 3 vaccine trial design: rethinking statistics for the 21st century","volume":"219","author":"Janani","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2026.128690_bb0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12879-021-06141-4","article-title":"Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis","volume":"21","author":"Ledesma","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0120","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0125","series-title":"A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72\/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine","author":"Dagnew","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128690_bb0130","series-title":"Modern epidemiology: Wolters Kluwer Health\/Lippincott Williams & Wilkins Philadelphia","author":"Rothman","year":"2008"},{"key":"10.1016\/j.vaccine.2026.128690_bb0135","series-title":"Guideline on clinical evaluation of vaccines","author":"Agency EM","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128690_bb0140","series-title":"Guidance for industry\u2014general principles for the development of vaccines to protect against global infectious diseases 2011","author":"Food U, Administration D","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128690_bb0145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00005792-200205000-00005","article-title":"Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy","volume":"81","author":"Shelburne Iii","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.vaccine.2026.128690_bb0155","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(10)70170-5","article-title":"International network for the study of HIVaI. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions","volume":"10","author":"Haddow","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0160","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128690_bb0165","series-title":"WHO operational handbook on tuberculosis. Module 1: Prevention-tuberculosis preventive treatment","author":"Organization WH","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128690_bb0170","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128690_bb0175","series-title":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","first-page":"42","author":"JG","year":"2008"},{"key":"10.1016\/j.vaccine.2026.128690_bb0180","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2352-3018(25)00124-9","article-title":"Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial","volume":"12","author":"Dagnew","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2026.128690_bb0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128690_bb0190","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa520","article-title":"Prevalence and risk factors for Mycobacterium tuberculosis infection among adolescents in rural South Africa","volume":"8","author":"Mzembe","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128690_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003753","article-title":"Burden of tuberculosis in underserved populations in South Africa: a systematic review and meta-analysis","volume":"4","author":"Holtgrewe","year":"2024","journal-title":"PLoS Glob Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T22:26:54Z","timestamp":1783290414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0264410X26004986"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128690","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and feasibility considerations for a phase 3 efficacy trial of the M72\/AS01E-4 tuberculosis vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128690"}}